When and how to use maraviroc in HIV-infected patients.
Soriano
Vincent
V
Perno
Carlo-Federico
CF
Kaiser
Rolf
R
Calvez
Vincent
V
Gatell
Jose M
JM
di Perri
Giovanni
G
Pillay
Deenan
D
Rockstroh
Juergen
J
Geretti
Anna María
AM
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000502:physiology; D023581:HIV Fusion Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D000077592:Maraviroc; D014230:Triazoles / Q000493:pharmacokinetics / Q000627:therapeutic use*; D056189:Viral Tropism / Q000502:physiology*
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D014230:Triazoles; D000077592:Maraviroc